04/11/2010 (6:09 pm)
Achaogen raises $56 million
In its third round of venture funding, Achaogen Inc. raised $56 million.
The San Francisco company seeks drugs to fight bacteria that are resistant to existing drugs. It’s also working on drugs aimed at bubonic plague and other bugs attractive to possible terrorists.
Frazier Healthcare Ventures, a new investor, led this round and put Robert More on Achaogen’s board of directors.
Alta Partners, 5 AM Ventures, Arch Venture Partners, Domain Associates, Venrock Associates, Versant Ventures and the Wellcome Trust also gave money.
Kevin Judice is CEO of Achaogen.
No Comments
No comments yet.
RSS feed for comments on this post.
Sorry, the comment form is closed at this time.